目的 利用超高效液相色谱串联Qda质谱法对单抗的N糖谱进行定性和定量分析。方法 对单抗Fc上的N糖链利用糖苷酶F进行酶切释放,然后用RapiFluor-MS染料进行标记,通过Qda质谱对N糖进行糖型鉴别、荧光检测器进行定量检测。结果 超高效液相色谱串联Qda质谱法能够准确的对单抗N糖进行定性定量检测,单个糖型的实测m/z值在理论值±0.5内。利用该方法对原研抗CD20人鼠嵌合单抗和生物类似药候选药物的N糖进行分析表明,3个候选药物的N糖谱与原研抗体基本一致,但在部分糖型种类和比例上存在一定的差异,总的岩藻糖修饰糖型比例基本一致。对CHO细胞、NS0细胞和SP2/0细胞表达的单抗N糖进行比对分析显示,3种细胞表达单抗的主要糖型为G0F-N、G0F、Man5、G1Fa、G1Fb和G2F,占总糖型比例的80%以上。相比于NS0细胞和SP2/0细胞,CHO细胞表达抗体糖型种类相对较为简单,共11种糖型。而NS0细胞和SP2/0细胞表达单抗糖型种类和结构较复杂,分别检测到22和26种糖型,其中含有多种复杂的唾液酸和半乳糖修饰糖型,虽然这些糖型所占比例较低,但可能与单抗的体内半衰期和免疫原性相关。结论 超高效液相色谱串联Qda质谱法作为快速准确的N糖分析方法,可应用于单抗N糖的质控研究中。
Abstract
OBJECTIVE To analyze the N-glycan profile of therapeutic antibodies by UPLC-Qda MS. METHODS The N-linked glycan in Fc region was released by PNGase F digestion and labeled by RapiFluor-MS, and labeled glycans were analyzed by UPLC-Qda MS. RESULTS The UPLC-Qda MS method showed good accuracy in N-glycan quantitaion and qualification, and the Δm/z value of individual N-glycan was in a range of ±0.5. Three similar biotherapeutic products (SBP) showed a nearly same N-glycan profile with the reference biotherapeutic products (RBP) and the total percentage of fucosylated glycans was comparable, only one fraction of N-glycans had some difference. The major N-glycans of antibodies expressed by CHO cells, NS0 cells and SP2/0 cells were G0F-N, G0F, Man5, G1Fa, G1Fb and G2F, accounting for above 80% of total glycans. Eleven glycoforms were detected in CHO cell expressed antibodies, 22 and 26 glycoforms were detected in NS0 cell and SP2/0 cell expressed antibodies respectively. The N-glycans of NS0 cell and SP2/0 cell expressed antibodies contained more sialylated and galactosylated complex glycoforms, which was related to the antibody half-life in vivo and immunogenicity. CONCLUSION The HILIC UPLC-Qda MS, as a fast and accurate analytical method, can be used in the quality control of N-glycan profile of antibody.
关键词
单克隆抗体 /
N糖基化修饰 /
Qda质谱 /
生物类似药 /
抗体依赖的细胞介导的细胞毒性作用
{{custom_keyword}} /
Key words
monoclonal antibody /
N-linked glycosylation /
Qda MS /
similar biotherapeutic product /
antibody-dependent cell-mediated cytotoxicity
{{custom_keyword}} /
中图分类号：
R917
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SLIWKOWSKI M X,MELLMAN I. Antibody therapeutics in cancer[J]. Science,2013,341(6151):1192-1198.
[2] GAO K,WANG J. The biopharmaceutical industry in China: history and future perspectives[J]. Front Med,2012,6(2):101-111.
[3] LIU L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins[J]. J Pharm Sci,2015,104(6):1866-1884.
[4] SHI H H,GOUDAR C T. Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans[J]. Biotechnol Bioeng,2014,111(10):1907-1919.
[5] CHUNG C H,MIRAKHUR B,CHAN E,et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose[J]. N Engl J Med,2008,358(11):1109-1117.
[6] LAUBER M A,YU Y Q,BROUSMICHE D W,et al. Rapid preparation of released N-glycans for HILIC analysis using a labeling reagent that facilitates sensitive fluorescence and ESI-MS detection[J]. Anal Chem,2015,87(10):5401-5409.
[7] REUSCH D,HABERGER M,MAIER B,et al. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods[J]. MAbs,2015,7(1):167-179.
[8] SZEKRÉNYES Á,PARK S S,SANTOS M,et al. Multi-site N-glycan mapping study 1: capillary electrophoresis-laser induced fluorescence[J]. MAbs,2016,8(1):56-64.
[9] WANG W B,WANG L,WANG X, et al. Comparative study of N-linked glycan Profile of Human/Murine Chimeric anti-CD20 antibodies by Capillary Electrophoresis [J]. Chin J New Drug(中国新药杂志),2015,20:2312-2316.
[10] DOROKHOV Y L,SHESHUKOVA E V,KOSOBOKOVA E N, et al. Functional role of carbohydrate residues in human immunoglobulin G and therapeutic monoclonal antibodies [J]. Biochemistry(Mosc),2016,81(8):835-857.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家“重点研发计划”生物安全关键技术研发专项资助项目 (2016YFC1200904)
{{custom_fund}}
PDF(1769 KB)
